Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Observations and Projections of Heat Waves in South America.

Feron S, Cordero RR, Damiani A, Llanillo PJ, Jorquera J, Sepulveda E, Asencio V, Laroze D, Labbe F, Carrasco J, Torres G.

Sci Rep. 2019 Jun 3;9(1):8173. doi: 10.1038/s41598-019-44614-4.

2.

Elemental and Mineralogical Composition of the Western Andean Snow (18°S-41°S).

Alfonso JA, Cordero RR, Rowe PM, Neshyba S, Casassa G, Carrasco J, MacDonell S, Lambert F, Pizarro J, Fernandoy F, Feron S, Damiani A, Llanillo P, Sepulveda E, Jorquera J, Garcia B, Carrera JM, Oyola P, Kang CM.

Sci Rep. 2019 May 31;9(1):8130. doi: 10.1038/s41598-019-44516-5.

3.

Do T90 and SaO2 nadir identify a different phenotype in obstructive sleep apnea?

Labarca G, Campos J, Thibaut K, Dreyse J, Jorquera J.

Sleep Breath. 2019 May 12. doi: 10.1007/s11325-019-01860-0. [Epub ahead of print]

PMID:
31081538
4.

Effects of soiling on photovoltaic (PV) modules in the Atacama Desert.

Cordero RR, Damiani A, Laroze D, MacDonell S, Jorquera J, Sepúlveda E, Feron S, Llanillo P, Labbe F, Carrasco J, Ferrer J, Torres G.

Sci Rep. 2018 Sep 17;8(1):13943. doi: 10.1038/s41598-018-32291-8.

5.

CPAP in patients with obstructive sleep apnea and type 2 diabetes mellitus: Systematic review and meta-analysis.

Labarca G, Reyes T, Jorquera J, Dreyse J, Drake L.

Clin Respir J. 2018 Aug;12(8):2361-2368. doi: 10.1111/crj.12915. Review.

PMID:
30073792
6.

Differences between manual and automatic analysis in determining the severity of obstructive sleep apnea using home sleep apnea testing.

Labarca G, Dreyse J, Salas C, Contreras A, Nazar G, Gaete MI, Jorquera J.

Sleep Med. 2018 Jul;47:66-71. doi: 10.1016/j.sleep.2018.03.015. Epub 2018 Apr 7.

PMID:
29772418
7.

Ultraviolet radiation in the Atacama Desert.

Cordero RR, Damiani A, Jorquera J, Sepúlveda E, Caballero M, Fernandez S, Feron S, Llanillo PJ, Carrasco J, Laroze D, Labbe F.

Antonie Van Leeuwenhoek. 2018 Aug;111(8):1301-1313. doi: 10.1007/s10482-018-1075-z. Epub 2018 Mar 31.

PMID:
29605897
8.
9.

Extrapulmonary effects of continuous airway pressure on patients with obstructive sleep apnoea: protocol for an overview of systematic reviews.

Labarca G, Ortega F, Arenas A, Reyes T, Rada G, Jorquera J.

BMJ Open. 2017 Jun 30;7(6):e015315. doi: 10.1136/bmjopen-2016-015315. Review.

10.

Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role.

Bozzo J, Jorquera JI.

Expert Rev Anti Infect Ther. 2017 Jun;15(6):585-604. doi: 10.1080/14787210.2017.1328278. Epub 2017 May 15. Review.

PMID:
28480779
11.

Choristoma: A rare congenital tumor of the tongue.

Jorquera JP, Rubio-Palau J, Cazalla AA, Rodríguez-Carunchio L.

Ann Maxillofac Surg. 2016 Jul-Dec;6(2):311-313. doi: 10.4103/2231-0746.200342.

12.

Neutralizing capacity of inhibitors on FVIII is lower for natural FVIII/VWF complex than for isolated FVIII: in vitro comparative study in eleven different therapeutic FVIII concentrates.

Bravo MI, Ortiz AM, Costa M, Grancha S, Jorquera JI.

Haemophilia. 2016 Jul;22(4):e341-4. doi: 10.1111/hae.12975. Epub 2016 Jun 28. No abstract available.

PMID:
27354216
13.

The Solar Spectrum in the Atacama Desert.

Cordero RR, Damiani A, Seckmeyer G, Jorquera J, Caballero M, Rowe P, Ferrer J, Mubarak R, Carrasco J, Rondanelli R, Matus M, Laroze D.

Sci Rep. 2016 Mar 2;6:22457. doi: 10.1038/srep22457.

14.

Culture of human mesenchymal stem cells using a candidate pharmaceutical grade xeno-free cell culture supplement derived from industrial human plasma pools.

Díez JM, Bauman E, Gajardo R, Jorquera JI.

Stem Cell Res Ther. 2015 Mar 13;6:28. doi: 10.1186/s13287-015-0016-2.

15.
16.

Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study.

Boada M, Ramos-Fernández E, Guivernau B, Muñoz FJ, Costa M, Ortiz AM, Jorquera JI, Núñez L, Torres M, Páez A.

Neurologia. 2016 Sep;31(7):473-81. doi: 10.1016/j.nrl.2014.02.003. Epub 2014 Jul 9. Review. English, Spanish.

17.

UV irradiance and albedo at Union Glacier Camp (Antarctica): a case study.

Cordero RR, Damiani A, Ferrer J, Jorquera J, Tobar M, Labbe F, Carrasco J, Laroze D.

PLoS One. 2014 Mar 5;9(3):e90705. doi: 10.1371/journal.pone.0090705. eCollection 2014.

18.

Robustness of nanofiltration for increasing the viral safety margin of biological products.

Caballero S, Diez JM, Belda FJ, Otegui M, Herring S, Roth NJ, Lee D, Gajardo R, Jorquera JI.

Biologicals. 2014 Mar;42(2):79-85. doi: 10.1016/j.biologicals.2013.10.003. Epub 2014 Jan 29.

PMID:
24485384
19.

Downwelling and upwelling radiance distributions sampled under cloudless conditions in Antarctica.

Cordero RR, Damiani A, Ferrer J, Rayas J, Jorquera J, Tobar M, Labbe F, Laroze D.

Appl Opt. 2013 Sep 1;52(25):6287-94. doi: 10.1364/AO.52.006287.

PMID:
24085089
20.

In vitro amyloid-β binding and inhibition of amyloid-β self-association by therapeutic albumin.

Milojevic J, Costa M, Ortiz AM, Jorquera JI, Melacini G.

J Alzheimers Dis. 2014;38(4):753-65. doi: 10.3233/JAD-131169.

PMID:
24072068
21.

Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.

José M, Marzo N, Pons B, Herrerias A, López L, Faro M, López M, Jorquera JI.

Biologicals. 2013 Nov;41(6):393-9. doi: 10.1016/j.biologicals.2013.08.002. Epub 2013 Sep 17.

PMID:
24051302
23.

Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.

Cai K, Gröner A, Dichtelmüller HO, Fabbrizzi F, Flechsig E, Gajardo R, von Hoegen I, Jorquera JI, Kempf C, Kreil TR, Lee DC, Moscardini M, Pölsler G, Roth NJ.

Transfusion. 2013 Sep;53(9):1894-905. doi: 10.1111/trf.12050. Epub 2012 Dec 17.

PMID:
23252676
24.

Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.

Grancha S, Ortiz AM, Marañón C, Hampel K, Moret A, Zimmermann B, Jorquera JI, Aznar JA.

Haemophilia. 2012 Nov;18(6):982-9. doi: 10.1111/j.1365-2516.2012.02858.x. Epub 2012 May 30.

PMID:
22646163
25.

Therapeutic albumin binding to remove amyloid-β.

Costa M, Ortiz AM, Jorquera JI.

J Alzheimers Dis. 2012;29(1):159-70. doi: 10.3233/JAD-2012-111139.

PMID:
22232005
26.

Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates.

Grancha S, Navajas R, Marañón C, Paradela A, Albar JP, Jorquera JI.

Haemophilia. 2011 Jul;17(4):709-10. doi: 10.1111/j.1365-2516.2010.02454.x. Epub 2011 Feb 7. No abstract available.

PMID:
21299741
27.

Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent.

Diez JM, Caballero S, Belda F, Otegui M, Gajardo R, Jorquera JI.

Biologicals. 2010 Nov;38(6):670-4. doi: 10.1016/j.biologicals.2010.08.003. Epub 2010 Sep 22.

PMID:
20863716
28.

[The capacity of albumin to bind to beta-amyloid].

Costa M, Ortiz AM, Jorquera JI.

Rev Neurol. 2010 Mar 16;50 Suppl 5:S1-4. Spanish.

29.

Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.

Caballero S, Nieto S, Gajardo R, Jorquera JI.

Biologicals. 2010 Jul;38(4):486-93. doi: 10.1016/j.biologicals.2010.02.008. Epub 2010 Mar 29.

PMID:
20350815
30.

Relevance of quantitative measurements of anti-Abeta antibodies in therapeutic intravenous immunoglobulin using synthetic peptides.

Jorquera JI.

Int Immunopharmacol. 2010 Mar;10(3):373-4; author reply 375-6. doi: 10.1016/j.intimp.2009.12.007. Epub 2009 Dec 16. No abstract available.

PMID:
20018258
31.

Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy.

Jorquera JI.

Clin Exp Immunol. 2009 Sep;157 Suppl 1:17-21. doi: 10.1111/j.1365-2249.2009.03953.x. Erratum in: Clin Exp Immunol. 2009 Sep;157(3):446.

32.

Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.

Diez JM, Caballero S, Belda FJ, Otegui M, Gajardo R, Jorquera JI.

Haemophilia. 2009 Nov;15(6):1249-57. doi: 10.1111/j.1365-2516.2009.02067.x. Epub 2009 Jun 26.

PMID:
19563480
33.

Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.

Dichtelmüller HO, Biesert L, Fabbrizzi F, Gajardo R, Gröner A, von Hoegen I, Jorquera JI, Kempf C, Kreil TR, Pifat D, Osheroff W, Poelsler G.

Transfusion. 2009 Sep;49(9):1931-43. doi: 10.1111/j.1537-2995.2009.02222.x. Epub 2009 May 20.

PMID:
19497061
34.

Successful treatment of severe hepatopulmonary syndrome with a sequential use of TIPS placement and liver transplantation.

Benítez C, Arrese M, Jorquera J, Godoy I, Contreras A, Loyola S, Domínguez P, Jarufe N, Martínez J, Pérez-Ayuso RM.

Ann Hepatol. 2009 Jan-Mar;8(1):71-4.

35.

Safety procedures of coagulation factors.

Jorquera JI.

Haemophilia. 2007 Dec;13 Suppl 5:41-6. doi: 10.1111/j.1365-2516.2007.01578.x.

PMID:
18078396
36.

Effect of temperature on plasma freezing under industrial conditions.

Bravo MI, Grancha S, Jorquera JI.

Pharmeur Sci Notes. 2006 Aug;2006(1):31-5.

PMID:
17694644
37.
38.

Critical factors influencing prion inactivation by sodium hydroxide.

Bauman PA, Lawrence LA, Biesert L, Dichtelmüller H, Fabbrizzi F, Gajardo R, Gröner A, Jorquera JI, Kempf C, Kreil TR, von Hoegen I, Pifat DY, Petteway SR Jr, Cai K.

Vox Sang. 2006 Jul;91(1):34-40.

PMID:
16756599
39.

Physiological and clinical effects of diurnal noninvasive ventilation in hypercapnic COPD.

Díaz O, Bégin P, Andresen M, Prieto ME, Castillo C, Jorquera J, Lisboa C.

Eur Respir J. 2005 Dec;26(6):1016-23.

40.

[Necrotizing pneumonia due to Rhodococcus equi in non HIV immunocompromised host. Case report and review].

Rabagliati R, Morales A, Baudrand R, Jorquera J, Oddó D, García P, Carmona MC, Cisternas M, Huete A.

Rev Chilena Infectol. 2005 Jun;22(2):155-60. Epub 2005 May 12. Review. Spanish.

41.

Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples under long-term storage.

José M, Gajardo R, Jorquera JI.

Biologicals. 2005 Mar;33(1):9-16.

PMID:
15713552
42.

Neutralization of measles virus infectivity and antibody-dependent cell-mediated cytotoxicity activity against an Epstein-Barr virus-infected cell line by intravenous immunoglobulin G [corrected].

Colomar M, Puga I, López M, Massot M, Jorquera JI, Reina M, Vilaró S, Espel E.

Clin Diagn Lab Immunol. 2003 Sep;10(5):751-6. Erratum in: Clin Diagn Lab Immunol. 2003 Nov;10(6):1161.

43.

[Effect of ipratropium bromide on lung dynamic hyperinflation in patients with chronic obstructive lung disease].

Jorquera J, Díaz O, Lisboa C.

Rev Med Chil. 2003 Jun;131(6):605-12. Spanish.

PMID:
12942587
44.

The effect of storage at different temperatures on the stability of Hepatitis C virus RNA in plasma samples.

José M, Curtu S, Gajardo R, Jorquera JI.

Biologicals. 2003 Mar;31(1):1-8.

PMID:
12623054
45.

[The six minute walking test elicits lung hyperinflation in patients with severe chronic obstructive lung disease].

Reid R, Díaz O, Jorquera J, Lisboa C.

Rev Med Chil. 2001 Oct;129(10):1171-8. Spanish.

PMID:
11775344
46.

Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

Gensana M, Altisent C, Aznar JA, Casaña P, Hernández F, Jorquera JI, Magallón M, Massot M, Puig L.

Haemophilia. 2001 Jul;7(4):369-74.

PMID:
11442641
47.

[No ELISA detectable alterations in immunogenicity following dry-hear treatment (72 hours at 80 degrees C) of FANHDI].

Bravo MI, Massot M, Jorquera JI.

Sangre (Barc). 1999 Dec;44(6):412-7. Spanish.

PMID:
10822752
48.

von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions.

Rivera J, Escolar G, Casamiquela R, Bravo MI, Jorquera JI, Castillo R, Ordinas A, Vicente V.

Haematologica. 1999 Jan;84(1):5-11.

49.

Functional compensation of the low platelet count by increased individual platelet size in a patient with May-Hegglin anomaly presenting with acute myocardial infarction.

Goto S, Kasahara H, Sakai H, Goto M, Ono M, Ikeda Y, Jorquera JI, Bravo MI, Handa S.

Int J Cardiol. 1998 Apr 1;64(2):171-7.

PMID:
9688436
50.

[Functionality of von Willebrand factor present in Fanhdi: adhesion to the vascular subendothelium in vitro].

Escolar G, Viñas M, Pino M, Casamiquela R, Jorquera JI.

Sangre (Barc). 1997 Oct;42(5):377-81. Spanish.

PMID:
9424737

Supplemental Content

Loading ...
Support Center